多形性膠芽腫治療薬の世界市場2015-2019...市場調査レポートについてご紹介

【英文タイトル】Global Glioblastoma Multiforme Therapeutics Market 2015-2019

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology

05.Introduction

06.Market Landscape
06.1 Global Glioblastoma Multiforme Therapeutics Market
06.1.1 Market Overview
06.1.2 Market Size and Forecast
06.2 Five Forces Analysis

07.Market Segmentation by Route of Administration
07.1 Oral
07.2 Parenteral

08.Market Segmentation by Type of Molecule
08.1 Small Molecules
08.2 Biologics

09.Geographical Segmentation
09.1 Glioblastoma Multiforme Therapeutics Market in Americas
09.1.1 Market Overview
09.1.2 Market Size and Forecast
09.2 Glioblastoma Multiforme Therapeutics Market in EMEA
09.2.1 Market Overview
09.2.2 Market Size and Forecast
09.3 Glioblastoma Multiforme Therapeutics Market in APAC
09.3.1 Market Overview
09.3.2 Market Size and Forecast

10.Buying Criteria

11.Pipeline Portfolio

12.Market Growth Drivers

13.Drivers and their Impact

14.Market Challenges

15.Impact of Drivers and Challenges

16.Market Trends

17.Trends and their Impact

18.Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2014
18.2.1 Arbor Pharmaceuticals
18.2.2 Bristol-Myers Squibb
18.2.3 Eisai
18.2.4 F. Hoffmann-La Roche
18.2.5 Merck
18.3 Other and Possible Future Prominent Vendors

19.Key Vendor Analysis
19.1 Arbor Pharmaceuticals
19.1.1 Key Facts
19.1.2 Business Overview
19.1.3 Business Strategy
19.1.4 Recent Developments
19.1.5 SWOT Analysis
19.2 Bristol-Myers Squibb
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Key Product Offerings
19.2.4 Revenue by Geography
19.2.5 Business Strategy
19.2.6 Key Information
19.2.7 SWOT Analysis
19.3 Eisai
19.3.1 Key Facts
19.3.2 Business Overview
19.3.3 Comparison between Revenue, Operating Income, and Net Income
19.3.4 Sales by Geography
19.3.5 Business Strategy
19.3.6 Key Information
19.3.7 SWOT Analysis
19.4 F. Hoffmann-La Roche
19.4.1 Key Facts
19.4.2 Business Overview
19.4.3 Business Segmentation
19.4.4 Business Segmentation by Revenue 2012 and 2013
19.4.5 Sales by Geography
19.4.6 Business Strategy
19.4.7 Key Information
19.4.8 SWOT Analysis
19.5 Merck
19.5.1 Key Facts
19.5.2 Business Overview
19.5.3 Business Segmentation by Revenue 2013
19.5.4 Business Segmentation by Revenue 2012 and 2013
19.5.5 Sales by Geography
19.5.6 Business Strategy
19.5.7 Key Developments
19.5.8 SWOT Analysis

20.Other Reports in this Series

[List of Exhibits]

Exhibit 1: Market Research Methodology
Exhibit 2: Snapshot of the Global Glioblastoma Multiforme Therapeutics Market
Exhibit 3: Global Glioblastoma Multiforme Therapeutics Market 2014-2019 ($ millions)
Exhibit 4: Key Takeaways: Global Glioblastoma Multiforme Therapeutics Market
Exhibit 5: Segmentation of Global Glioblastoma Multiforme Therapeutics Market by Route of Administration
Exhibit 6: Segmentation of Global Glioblastoma Multiforme Therapeutics Market by Type of Molecule
Exhibit 7: Segmentation of Global Glioblastoma Multiforme Therapeutics Market by Geography 2014
Exhibit 8: Glioblastoma Multiforme Therapeutics Market in Americas 2014-2019 ($ millions)
Exhibit 9: Glioblastoma Multiforme Therapeutics Market in EMEA 2014-2019 ($ millions)
Exhibit 10: Glioblastoma Multiforme Therapeutics Market in APAC 2014-2019 ($ millions)
Exhibit 11: Global Glioblastoma Multiforme Therapeutics Market by Geography 2014-2019
Exhibit 12: Glioblastoma Multiforme: Pipeline Portfolio
Exhibit 13: Drug Candidates by Stage of Development (percentage)
Exhibit 14: Drivers of the Global Glioblastoma Multiforme Therapeutics Market
Exhibit 15: Challenges of the Global Glioblastoma Multiforme Therapeutics Market
Exhibit 16: Trends in the Global Glioblastoma Multiforme Therapeutics Market
Exhibit 17: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
Exhibit 18: Bristol-Myers Squibb Co.: Geographical Segmentation by Revenue 2013
Exhibit 19: Eisai: Comparison between Revenue, Operating Income, and Net Income 2011-2013 ($ billions)
Exhibit 20: Eisai: Sales by Geography 2013 ($ billions)
Exhibit 21: F. Hoffmann-La Roche: Business Segmentation2013
Exhibit 22: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
Exhibit 23: F. Hoffmann-La Roche: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 24: F. Hoffmann-La Roche: Sales by Geography 2013 (Diagnostics Division)
Exhibit 25: Merck: Business Segmentation by Revenue 2013
Exhibit 26: Merck: Business Segmentation by Revenue 2012 and 2013 ($ billions)
Exhibit 27: Merck: Sales by Geography 2013


【レポート販売概要】

■ タイトル:多形性膠芽腫治療薬の世界市場2015-2019
■ 英文:Global Glioblastoma Multiforme Therapeutics Market 2015-2019
■ 発行日:2015年7月29日
■ 調査会社:Technavio
■ 商品コード:IRTNTR6606
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。